RT Journal Article
SR Electronic
T1 Association Between Proton Pump Inhibitors and the Risk of Intestinal Behçet Disease
JF The Journal of Rheumatology
JO J Rheumatol
FD The Journal of Rheumatology
SP jrheum.2024-0442
DO 10.3899/jrheum.2024-0442
A1 Murakami, Keita
A1 Arai, Junya
A1 Ihara, Sozaburo
A1 Hirata, Yoshihiro
A1 Tsuchida, Yumi
A1 Shoda, Hirofumi
A1 Tsuboi, Mayo
A1 Kurokawa, Ken
A1 Suzuki, Nobumi
A1 Kinoshita, Hiroto
A1 Hayakawa, Yoku
A1 Fujio, Keishi
A1 Fujishiro, Mitsuhiro
YR 2024
UL http://www.jrheum.org/content/early/2024/08/08/jrheum.2024-0442.abstract
AB Objective This study aimed to investigate the association between proton pump inhibitor (PPI) use and the incidence of intestinal Behçet disease (BD) in patients with BD.Methods A retrospective cohort study was conducted at The University of Tokyo Hospital, including patients with BD diagnosed between April 2005 and November 2023. Cox models and Kaplan-Meier analyses were used to evaluate hazard ratios (HRs) and cumulative incidence of intestinal BD, respectively. Secondary analyses were performed to assess the duration and dose-response relationship of PPI use.Results Among 194 patients with BD, 25.3% developed intestinal BD during a mean follow-up of 12 years. PPI users had a significantly higher incidence of intestinal BD compared to nonusers (adjusted HR 2.48, 95% CI 1.38-4.47, P = 0.002), with a confirmed duration/dose-dependent relationship. The cumulative incidence of intestinal BD was markedly elevated in PPI users (log-rank P < 0.001). The result was similar to that in the propensity score−matched cohort.Conclusion This study demonstrates a significant association between PPI use and increased incidence of intestinal BD in patients with BD. Caution in prescribing PPIs for patients with BD is warranted due to the potential risk of severe complications associated with intestinal BD.